NEK2 is a potential pan-cancer biomarker and immunotherapy target
Abstract Background NEK2 is a member of the NEKs family and plays an important role in cell mitosis. Increasing evidence suggests that NEK2 is associated with the development of multiple tumors, but systematic studies of NEK2 in cancer are still lacking. Therefore, we evaluated the prognostic value...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01519-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171809192345600 |
|---|---|
| author | Lanyue Zhang Yang Li Juexiao Deng Wenxin Liao Tingting Liu Fujin Shen |
| author_facet | Lanyue Zhang Yang Li Juexiao Deng Wenxin Liao Tingting Liu Fujin Shen |
| author_sort | Lanyue Zhang |
| collection | DOAJ |
| description | Abstract Background NEK2 is a member of the NEKs family and plays an important role in cell mitosis. Increasing evidence suggests that NEK2 is associated with the development of multiple tumors, but systematic studies of NEK2 in cancer are still lacking. Therefore, we evaluated the prognostic value of NEK2 in 33 cancers to elucidate the potential function of NEK2 in pan-cancers. Methods We investigated the role of NEK2 in pan-cancers utilizing The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. Additionally, we analyzed the association between NEK2 gene expression across various cancers, protein expression, the tumor microenvironment (TME), and drug sensitivity using several software and web platforms.The potential oncogenic role of NEK2 was initially explored using bioinformatics methods. Furthermore, we conducted in vitro experiments to preliminarily validate the function of NEK2 in cervical cancer. Results NEK2 is overexpressed in almost all tumors, and mutation of NEK2 are associated with a poorer tumor prognosis. In addition, the correlation between NEK2 and immune features such as immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), Microsatellite instability(MSI) etc. suggest that NEK2 could potentially be applied in the immunotherapy of tumors. Conclusion NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy. |
| format | Article |
| id | doaj-art-55d25d0d4bf340a8b2054892fccd15b7 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-55d25d0d4bf340a8b2054892fccd15b72024-11-10T12:31:26ZengSpringerDiscover Oncology2730-60112024-11-0115111810.1007/s12672-024-01519-7NEK2 is a potential pan-cancer biomarker and immunotherapy targetLanyue Zhang0Yang Li1Juexiao Deng2Wenxin Liao3Tingting Liu4Fujin Shen5Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan UniversityAbstract Background NEK2 is a member of the NEKs family and plays an important role in cell mitosis. Increasing evidence suggests that NEK2 is associated with the development of multiple tumors, but systematic studies of NEK2 in cancer are still lacking. Therefore, we evaluated the prognostic value of NEK2 in 33 cancers to elucidate the potential function of NEK2 in pan-cancers. Methods We investigated the role of NEK2 in pan-cancers utilizing The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. Additionally, we analyzed the association between NEK2 gene expression across various cancers, protein expression, the tumor microenvironment (TME), and drug sensitivity using several software and web platforms.The potential oncogenic role of NEK2 was initially explored using bioinformatics methods. Furthermore, we conducted in vitro experiments to preliminarily validate the function of NEK2 in cervical cancer. Results NEK2 is overexpressed in almost all tumors, and mutation of NEK2 are associated with a poorer tumor prognosis. In addition, the correlation between NEK2 and immune features such as immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), Microsatellite instability(MSI) etc. suggest that NEK2 could potentially be applied in the immunotherapy of tumors. Conclusion NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy.https://doi.org/10.1007/s12672-024-01519-7NEK2Pan-cancersDiagnosisPrognosisTumor immunity |
| spellingShingle | Lanyue Zhang Yang Li Juexiao Deng Wenxin Liao Tingting Liu Fujin Shen NEK2 is a potential pan-cancer biomarker and immunotherapy target Discover Oncology NEK2 Pan-cancers Diagnosis Prognosis Tumor immunity |
| title | NEK2 is a potential pan-cancer biomarker and immunotherapy target |
| title_full | NEK2 is a potential pan-cancer biomarker and immunotherapy target |
| title_fullStr | NEK2 is a potential pan-cancer biomarker and immunotherapy target |
| title_full_unstemmed | NEK2 is a potential pan-cancer biomarker and immunotherapy target |
| title_short | NEK2 is a potential pan-cancer biomarker and immunotherapy target |
| title_sort | nek2 is a potential pan cancer biomarker and immunotherapy target |
| topic | NEK2 Pan-cancers Diagnosis Prognosis Tumor immunity |
| url | https://doi.org/10.1007/s12672-024-01519-7 |
| work_keys_str_mv | AT lanyuezhang nek2isapotentialpancancerbiomarkerandimmunotherapytarget AT yangli nek2isapotentialpancancerbiomarkerandimmunotherapytarget AT juexiaodeng nek2isapotentialpancancerbiomarkerandimmunotherapytarget AT wenxinliao nek2isapotentialpancancerbiomarkerandimmunotherapytarget AT tingtingliu nek2isapotentialpancancerbiomarkerandimmunotherapytarget AT fujinshen nek2isapotentialpancancerbiomarkerandimmunotherapytarget |